In a recently reported clinical trial, an aurora kinase A inhibitor, alisertib, combined with paclitaxel, had significantly improved PFS compared to paclitaxel alone in patients with cMYC-positive SCLC. Here, AURKA is linked to small cell lung carcinoma.